Rosa Arancibia, MD
Pulmonary Disease · Little Rock, ARNPI 1205125846
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (52.6%), food and beverage and education — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Intuitive Surgical at 30.0% of the total. Reporting peaked in 2023 at $1,873 and has fallen 53.7% since, to $867 in 2025.
Across 97 payments — averaging $46.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$1K
- Johnson & Johnson$803
- AstraZeneca$376
- Boehringer Ingelheim$360
- Boston Scientific$339
- GSK$218
- plus $1K from 15 others
What the payments were for
- Travel & lodging$2,36053%
- Food & beverage$2,01345%
- Education$1143%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 6 | $1,345 |
| Johnson & Johnson(2 entities) | 3 | $803 |
| AstraZeneca | 21 | $376 |
| Boehringer Ingelheim | 14 | $360 |
| Boston Scientific | 2 | $339 |
| GSK | 9 | $218 |
| ANI Pharmaceuticals, Inc. | 10 | $214 |
| Actelion Pharmaceuticals US, Inc. | 5 | $186 |
| Galvanize Therapeutics, Inc | 2 | $139 |
| AbbVie(2 entities) | 6 | $113 |
| Insmed, Inc. | 3 | $71 |
| Inogen, Inc. | 3 | $62 |
| Merck | 3 | $59 |
| United Therapeutics Corporation | 3 | $56 |
| Bayer | 1 | $27 |
| Lilly USA, LLC | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Amgen | 1 | $24 |
| Gilead | 1 | $16 |
| Electromed, Inc. | 1 | $15 |
| Advanced Respiratory, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,487 in reported general payments places this provider in the 55th percentile of 102 pulmonary disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 28 | $678,942 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 296 | $266,646 |
| OfevNintedanib Esylate | 18 | $186,060 |
| Ambrisentan | 28 | $103,790 |
| Fasenra PenBenralizumab | 16 | $92,425 |
| Incruse ElliptaUmeclidinium Bromide | 170 | $84,212 |
| FasenraBenralizumab | 14 | $79,571 |
| Breo ElliptaFluticasone/Vilanterol | 81 | $44,024 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 619 | $31,305 |
| Spiriva RespimatTiotropium Bromide | 40 | $27,909 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 110 | $20,847 |
| SymbicortBudesonide/Formoterol Fumarate | 54 | $18,469 |
| Tadalafil | 12 | $10,563 |
| Wixela InhubFluticasone Propion/Salmeterol | 32 | $7,844 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 26 | $5,588 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi | $186 | $678,94228 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Arnuity Ellipta | $218 | $398,545559 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $360 | $213,97058 claims |
| AstraZenecaFasenra, Symbicort | $376 | $98,04068 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Little Rock
- Nikhil MeenaLittle Rock$63K
- Hanan Khadam-MakhoulLittle Rock$15K
- Raghu ReddyLittle Rock$13K
- Eyad AbochaleLittle Rock$11K
- Krishna Siva Sai KakkeraLittle Rock$11K
- Samer HomsiLittle Rock$9K
- Nathan HillLittle Rock$9K
- Jose CaceresLittle Rock$6K
- Moeezullah BegLittle Rock$5K
- Nancy RectorLittle Rock$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.